Floatz logo

[225Ac]Ac-AKY-1189

Urothelial Carcinoma Bladder

Aktis Oncology, Inc.radiopharmaceuticalPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Urothelial Carcinoma Bladder cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
Atezolizumab
KaliVir Immunotherapeutics
Phase 3BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Nivolumab
Nagoya University
Phase 3BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

[225Ac]Ac-AKY-1189 is also rated in:

hormone receptor-positive breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
cervical adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →